Product
PRT543
1 clinical trial
8 indications
Indication
Diffuse Large B-cell LymphomaIndication
MyelodysplasiaIndication
MyelofibrosisIndication
Adenoid Cystic CarcinomaIndication
Mantle Cell LymphomaIndication
Acute Myeloid LeukemiaIndication
Chronic Myelomonocytic LeukemiaClinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation, Dose Expansion Study of PRT543 in Patients With Advanced Solid Tumors and Hematologic MalignanciesStatus: Completed, Estimated PCD: 2022-11-16